Eigen Therapeutics, a Redwood City, CA-based oncology biotech startup, raised $7M in Seed funding.
The round was led by Josh Kopelman with participation from Builders VC, Kevin Mahaffey, Hawktail, Matthew De Silva, Varsha Rao, Bioverge, Alumni Ventures, and Mount Pleasant Ventures.
The company intends to use the funds to apply their novel high-throughput platform toward the development of priming therapies. Their initial programs are focused on hematological malignancies; in the future, their platform will allow them to spin up programs for other cancer indications, such as solid tumors.
Founded by an engineer and a scientist, Transon Nguyen and Kamran Ali, Eigen is focused on the development of “priming” therapies, therapies that help targeted therapies reach their full potential by addressing cancer heterogeneity, making cancer cells more vulnerable and/or making healthy cells more resilient to treatment. The company takes a two-step approach to treating cancer. The first step is a priming therapy, which essentially shines a spotlight on the cancer cells to make them more recognizable. They do this by increasing target expression across cancer cells.
FinSMEs
09/12/2022